Dianthus confirms early GO for Phase 3 CAPTIVATE CIDP trial

 

Dianthus misses Q4 2025 estimates with EPS -1.43, revenue $284,000, 

• Non-GAAP EPS was $-1.43 in Q4 2025, down 77% year over year.
• Q4 2025 revenue was $284,000, declining 79% year over year and missing estimates.
• Dianthus Therapeutics highlights $514.4 million cash runway into 2028 for Dianthus.
• Company reports Q4 and full-year 2025 results and updates clinical timelines for claseprubart and DNTH212 programs.
• Positive interim responder analysis in Phase 3 CAPTIVATE CIDP supports 300mg claseprubart dose selection for continued-evaluation and early GO decision.
• Study design streamlined with reduced enrollment targets following interim analysis findings in the Phase 3 trial.
• Higher-dose arm removed from the Phase 3 CAPTIVATE trial based on positive data for 300mg.

https://finviz.com/quote.ashx?t=DNTH&p=d